Tivic Health to Report Q2 2024 Financial Results and Corporate Update on August 14th Via Conference Call and Webcast

Rhea-AI Summary

Tivic Health Systems, Inc. (Nasdaq: TIVC), a bioelectronic medicine health tech company, has announced its plans to report Q2 2024 financial results and provide a corporate update on August 14, 2024. The company will host a pre-recorded conference call and webcast at 1:30 PM PT / 4:30 PM ET. The update will focus on Tivic's vagus nerve research program and its market potential. Shareholders and interested parties are invited to join the webcast and submit questions by August 11, 2024. The teleconference can be accessed toll-free at 888-506-0062 (US) or 973-528-0011 (International) using the participant access code 316159. A webcast link is also provided for those who prefer to join online.

Positive

• Tivic Health is conducting vagus nerve research, potentially expanding its bioelectronic medicine portfolio
• The company is maintaining investor relations through scheduled financial result announcements and corporate updates

Negative

• None.

SAN FRANCISCO--(BUSINESS WIRE)-- Tivic Health® Systems, Inc. (“Tivic Health”, Nasdaq: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced that it will report its Q2 2024 financial results and a corporate update via pre-recorded conference call and webcast on Wednesday, August 14 at 1:30 PM PT / 4:30 PM ET. Current shareholders, interested individuals and future investors are encouraged to join the webcast to hear the company executives provide a corporate update that will highlight the importance of Tivic’s vagus nerve research program and its market potential. The company invites questions to be submitted to ir@tivichealth.com by August 11, 2024.

Teleconference Details:

Toll Free: 888-506-0062
International: 973-528-0011
Participant Access Code: 316159

Webcast Link
https://www.webcaster4.com/Webcast/Page/2865/50901

About Tivic Health

Tivic Health is a commercial health tech company advancing the field of bioelectronic medicine. Tivic Health’s technology platforms leverage stimulation of the trigeminal, sympathetic, and vagus nerve structures. Tivic Health’s non-invasive and targeted approach to the treatment of inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic Health’s first commercial product ClearUP is an FDA approved, award-winning, handheld bioelectronic sinus device. ClearUP is clinically proven, doctor-recommended, and is available through online retailers and commercial distributors. For more information visit http://tivichealth.com @TivicHealth

Forward-Looking Statements

This press release may contain “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on Tivic Health Systems, Inc.’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. Accordingly, you are cautioned not to place undue reliance on such forward-looking statements. For a discussion of risks and uncertainties relevant to the company, and other important factors, see Tivic Health’s filings with the SEC, including, its Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, under the heading “Risk Factors”; as well as the company’s subsequent filings with the SEC. Forward-looking statements contained in this press release are made as of this date, and Tivic Health Systems, Inc. undertakes no duty to update such information except as required by applicable law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240806935582/en/

Media Contact:

Morgan Luke

Morgan.Luke@tivichealth.com

Investor Contact:

Hanover International, Inc.

ir@tivichealth.com

Source: Tivic Health Systems, Inc.

FAQ

When will Tivic Health (TIVC) report its Q2 2024 financial results?

Tivic Health (TIVC) will report its Q2 2024 financial results on August 14, 2024, via a pre-recorded conference call and webcast at 1:30 PM PT / 4:30 PM ET.

What is the focus of Tivic Health's (TIVC) upcoming corporate update?

The corporate update will highlight the importance of Tivic Health's vagus nerve research program and its market potential.

How can investors participate in Tivic Health's (TIVC) Q2 2024 earnings call?

Investors can join the teleconference by calling 888-506-0062 (US toll-free) or 973-528-0011 (International) with the participant access code 316159. Alternatively, they can access the webcast via the provided link.

What is the deadline for submitting questions for Tivic Health's (TIVC) Q2 2024 earnings call?

Questions for Tivic Health's Q2 2024 earnings call should be submitted to ir@tivichealth.com by August 11, 2024.